A federal judge cut short the first patent dance involving a biosimilar, calling it premature. Judge Maxine Chesney denied Sandoz Inc.’s request for declaratory judgment that the Enbrel (etanercept) biosimilar it’s developing doesn’t infringe two patents owned by Roche AG and exclusively licensed to Amgen Inc.